On June 23, Hengrui Medicine rose 3.73% in regular trading, trading at 57.45 HKD/share, with turnover of approximately 42.72 million HKD.

On the news front, the company announced on June 22 that the European Medicines Agency (EMA) has formally accepted the marketing authorization application for its rilvegostomab tablets. This marks the first self-developed innovative drug by Hengrui to be submitted for marketing approval in the European Union. The drug is indicated for combination with androgen deprivation therapy (ADT) for the treatment of adult male patients with high tumor burden metastatic hormone-sensitive prostate cancer (mHSPC).

The positive momentum is further supported by multiple recent catalysts, including Schroders increasing its stake to 5.11% on June 12, the NMPA approval of a new indication for its CDK4/6 inhibitor dalpiciclib isethionate tablets, and clinical trial approvals for HRS-7525 tablets and SHR-6914 injection. Additionally, the company confirmed it is continuing its A-share buyback program with a total fund of no less than 10 billion RMB and no more than 20 billion RMB, signaling management confidence.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)